On behalf of the Chinese Society of Clinical Oncology, Dr. Qin Shukui thanked the Sino-Cuban joint venture Biotech Pharma (BPL) for expanding the application of this drug here, beyond the therapy against nasopharyngeal cancer.

According to the researcher, the positive results of the Nimotuzumab clinical trial may benefit more patients with this type of cancer.

According to the doctor, despite the commonness of this condition, the results of treatment at a global level are very poor, that is why new advances are urgently needed and there is a great unmet clinical need.

He also praised the Cuban Academy of Sciences and the importance of the biomedical industry on the island.

jrr/arm/mem/idm